Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 18/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554810 | 0.86 | GPBAR1 (0.72) | GPBAR1ALDH1A1LMNA | |
| SCHEMBL27910275 | 0.85 | HSD17B10 (0.78) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL18065752 | 0.85 | GPBAR1 (1.00) | GPBAR1CYP3A4CYP2C19 | |
| SCHEMBL29791377 | 0.85 | GPBAR1 (1.00) | GPBAR1CYP3A4CYP2C19 | |
| SCHEMBL14765558 | 0.84 | MAPT (0.77) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL30395456 | 0.84 | HSD17B10 (0.76) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL10520547 | 0.84 | HSD17B10 (0.76) | GPBAR1CYP3A4CYP2C19HSD17B10LMNA | |
| SCHEMBL315858 | 0.84 | HSD17B10 (0.76) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL32679558 | 0.84 | HSD17B10 (0.76) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 | |
| SCHEMBL459354 | 0.84 | HSD17B10 (0.76) | GPBAR1CYP3A4CYP2C19HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | GPBAR1 365/4885CYP3A4 61/4885CYP2C19 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.